Genome-wide association study of cardiotoxicity in NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial

OBJECTIVES: The major clinical side-effect of the ERBB2 targeted breast cancer therapy, trastuzumab, is a decline in left ventricular ejection fraction (LVEF). Improved markers are needed to better identify patients susceptible to cardiotoxicity. METHODS: The NCCTG N9831 trial compared adjuvant doxo...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Pharmacogenet Genomics
Main Authors: Serie, DJ, Crook, JE, Necela, BM, Dockter, TJ, Wang, X, Asmann, YW, Fairweather, D, Bruno, KA, Colon-Otero, G, Perez, EA, Thompson, EA, Norton, N
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581215/
https://ncbi.nlm.nih.gov/pubmed/28763429
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000302
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker